News

Companies continue to share news about the data that will be presented at the 2024 ASRS meeting in Stockholm, Sweden.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss nonleaking cystoid macular edema and subretinal fluid out of proportion to optic disc edema in idiopathic intracranial hypertension in the setting of optic atrophy.

The organisation has secured £72.75 million for its new eye health centre

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

A novel formulation may prevent blood vessel growth and vascular leakage in the retina.

The companies are teaming up to reduce care gaps and improve eye and vision health by bringing diabetic retinopathy and other eye disease screening services to patients in their own homes and workplaces.

A novel formulation may prevent blood vessel growth and vascular leakage in the retina

A team of researchers at the Ohio State University found that in mice an enzyme related to cell growth and division is a culprit in the blood vessel invasion in the back of the eye that causes blurred central vision in wet AMD.

Ophthalmologist receives the Roger Steinert, MD, Legacy Award during the Octane Ophthalmology Tech Forum in Irvine, California.

Prescriptions with semaglutide (Wegovy, Ozempic, Novo Nordisk) are FDA approved to treat obesity and type 2 diabetes, respectively.

Chris Brittain, vice president, Global Head of Ophthalmology Product Development at Genentech, sat with Ophthalmology Times to discuss the company's plans with Susvimo following the FDA approval for relaunch.

GLP-1 receptor agonists, such as Wegovy, Ozempic and Novo Nordisk, are becoming more prolific

The company announced it has received FDA approval to relaunch Susvimo for intravitreal use via an ocular implant for treating people with wet AMD.

The company has secured $170 million (approximately €157 million) in Series B funding

NVK002 atropine 0.01% (Vyluma Inc.) “meaningfully slowed” myopia progression in myopic pediatric patients over a 36-month period.

Most respondents were unsure of how to seek treatment and see dry eye as something that must be learned to live with.

The company states this will enable movement toward US approval

The funding will go toward the continued clinical development of the company’s lead asset, AGTC-501 (laruparetigene zovaparvovec)

Technology offers increased usability, safety, and accuracy in MIGS procedures.

Extended daylight hours and plentiful outdoor space make Stockholm a memorable destination for meeting attendees

Ella Faktorovich, MD, sat with Ophthalmology Times to discuss an anti-inflammatory treatment protocol she has been using to treat recurrent erosions after corneal refractive surgery.

The pharmaceutical candidate is being evaluated as a potential treat for nAMD.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss a unique case of a 15-year-old who showed signs of meningioma with epithelial whirls and some psammoma bodies in the eye.

IKA Keratoconus Symposium and Controversies in Modern Eye Care shone brightly in May

42nd Annual Meeting in Stockholm, the Venice of the North

Comanagement is a key component for treatment of disease.

According to Genentech, faricimab-svoa is the first and only syringe prefilled with an FDA-approved bispecific antibody for the treatment of wet AMD, DME and RVO.